Frontiers in Health & Medicine: Future Trends and Investment Opportunities in the Field of Orthopedics
Time and Location
August 24, 2019, Saturday
Registration: 1:30-2:00 pm
Talk and Q&A: 2:00-5:00 pm
Yale Center Beijing
8 Jianguomenwai Avenue, 36th Floor, Tower B, IFC Building (Yong’anli Station, Exit C)
Registration and Fees
Advance Registration: RMB 100 for Yale/Harvard alumni; RMB 130 for others
Pay at the Door: RMB 160
Walk-ins are not accepted.
The language of the event will be Chinese.
On August 24, the Yale Healthcare Club of China and Harvard Club of Beijing will invite doctors, entrepreneurs, hospital directors and investors in orthopedics to discuss future trends and opportunities.
Yu Han (Yale MA '07)
Company Secretary & Director of Capital Markets, AK Medical Holdings Ltd.
Yu Han, Company Secretary & Director of Capital Markets of AK Medical Holdings Limited (1789 HK), is responsible for information disclosure, investors' relations, and strategic investment and M&A. She has led the IPO of the company on HKex in 2017.
Prior to AK Medical, she worked in the PBC School of Finance, Tsinghua University. Ms. Han also has rich experience in healthcare policy analysis, participating in the project of "Government Investment Model and Compensation Mechanism for Healthcare facilities" sponsored by Ministry of Finance of China and Asian Development Bank. She holds a Master degree in Statistics from Yale University.
Chief Physician, Associate Professor, MD & Master’s Supervisor at Department of Orthopedics, Peking University Third Hospital
Professor Li Zijian is a member of Chinese Association of Orthopedic Surgeons, deputy head of joint durgery group of Young Committee of Beijing Medical Association, found member of Chinese Elite Club of Orthopedics, lecturer of Arthroplasty Society in Asia. His clinical interests include complicated shoulder, knee, and hip joint replacement surgery, aseptic necrosis of femoral head, computer guided surgery technology, and 3D-printing technology. He is a translator of Exeter Hip Joint and the associate editor of Diagnostic Strategies for Surgery.
Director of New Business Development, Johnson & Johnson Medical (China) Ltd.
Michael Hua is the Head of New Business Development in Johnson & Johnson Medical China. He is responsible for driving Johnson & Johnson Medical China's inorganic growth initiatives through equity investments and strategic alliances.
Before joining Johnson & Johnson, Michael was the director at Ernst & Young in Australia and partner of Inorganic Growth Consulting at Adfaith Management. Michael received his Bachelor of Commerce Degree from the University of Adelaide and Postgraduate Diploma in Law from the University of London. He is a Chartered Accountant and is a CFA Charter holder.
Managing Director, SDIC Innovation Investment Management Co., Ltd.
Lu Hai is the Managing Director at SDIC Innovation Investment Management Co., Ltd., responsible for the investment in the pharmaceutical health sector. While at SDIC, he led more than equity investments projects, and served as a director responsible for post-investment management.
Lu Hai was the Director of Strategic Development for Asia Pacific in Stryker, and served as the Senior Manager of PwC USA and China's Consulting Department. Mr. Lu also worked in Abbott Laboratories and Valent Pharmaceuticals. He received a BA in chemistry and biology from the University of Minnesota and a Ph.D in pharmacy chemistry from the University of Utah.
Director and General Manager, Changzhou DingJian Medical
Weihe Zhang joined DingJian Medical as Director and General Manager since 2018. He was the former Vice General Manager and CMO of Double Medical (002901.SZ), and former Chairman of Baijia Biologics. Mr. Zhang has 13 years of managerial experience in the orthopedic medical device industry. His past reforms and innovations on sales and marketing left profound impact on his company and successfully helped it achieve market leading position.
Wei Peng (Yale MBA '13)
Principal, CITIC Private Equity
Wei Peng, Principal at CITIC PE, focuses on investments in the healthcare sector. He has led or participated in the fund's investments in DingJian Medical, HongXin Medical, Biosensors, and BeiGene in the past few years. Opportunities in Orthopedics is one of his main areas of focus.
Prior to CITIC PE, Wei worked as Senior Consultant at Monitor Group, providing strategy-related advisory service to many large healthcare companies. He holds an MBA from Yale University and BA from Shanghai Jiaotong University.